Dentatorubral-Pallidoluysian Atrophy (DRPLA)

Dentatorubral-Pallidoluysian Atrophy (DRPLA)

Pathway / Interaction Diagram

Overview

Dentatorubral-Pallidoluysian Atrophy (DRPLA) is a rare autosomal dominant neurodegenerative disorder classified among the polyglutamine (polyQ) diseases[@shimohata2013]. The disease is caused by an unstable CAG trinucleotide repeat expansion in the ATN1 gene (also known as the DRPLA gene), which encodes the protein atrophin-1[@yazawa2001]. DRPLA is characterized by progressive cerebellar ataxia, myoclonus, choreoathetosis, and dementia, with onset typically occurring in adulthood or, in juvenile forms, during childhood[@tsuji2012].

DRPLA belongs to a family of neurodegenerative disorders that includes Huntington's disease (HD), spinocerebellar ataxias (SCAs), and spinal bulbar muscular atrophy (Kennedy disease), all of which involve polyglutamine expansions that lead to abnormal protein aggregation, transcriptional dysregulation, and neuronal dysfunction[@nucifora2022].

Epidemiology

Dentatorubral-Pallidoluysian Atrophy (DRPLA)

Pathway / Interaction Diagram

Overview

Dentatorubral-Pallidoluysian Atrophy (DRPLA) is a rare autosomal dominant neurodegenerative disorder classified among the polyglutamine (polyQ) diseases[@shimohata2013]. The disease is caused by an unstable CAG trinucleotide repeat expansion in the ATN1 gene (also known as the DRPLA gene), which encodes the protein atrophin-1[@yazawa2001]. DRPLA is characterized by progressive cerebellar ataxia, myoclonus, choreoathetosis, and dementia, with onset typically occurring in adulthood or, in juvenile forms, during childhood[@tsuji2012].

DRPLA belongs to a family of neurodegenerative disorders that includes Huntington's disease (HD), spinocerebellar ataxias (SCAs), and spinal bulbar muscular atrophy (Kennedy disease), all of which involve polyglutamine expansions that lead to abnormal protein aggregation, transcriptional dysregulation, and neuronal dysfunction[@nucifora2022].

Epidemiology

DRPLA is most prevalent in Japan, where it accounts for approximately 2-5% of all autosomal dominant cerebellar ataxias[@saito2015]. The prevalence in Japan is estimated at 0.5-1.0 per 100,000 population[@nishiyama1994]. The disease has been reported in other populations worldwide, though much less frequently, including cases in Europe, North America, and Asia[@burke1998].

The age of onset varies significantly and is inversely correlated with the number of CAG repeats[@ikeuchi1996]:

• Juvenile-onset DRPLA: onset before 20 years, typically associated with 65-88 repeats
• Adult-onset DRPLA: onset after 20 years, typically associated with 48-60 repeats

Genetics

Gene Structure

The ATN1 gene is located on chromosome 12p13.31 and consists of 10 exons spanning approximately 13 kb of genomic DNA[@masuda1996]. The CAG repeat is located in exon 5 and encodes a polyglutamine tract in the N-terminal region of the atrophin-1 protein[@nagafuchi1994].

Pathogenic Mechanism

The expanded CAG repeat translates into an abnormal polyglutamine tract in the atrophin-1 protein[@nucifora2001]. This polyglutamine expansion leads to:

Inheritance

DRPLA follows an autosomal dominant inheritance pattern with complete penetrance[@tsuji2002]. The disease exhibits anticipation, meaning that successive generations tend to have earlier onset and more severe symptoms, which is attributable to intergenerational instability of the CAG repeat, particularly during paternal transmission[@ikeuchi1997].

Pathophysiology

Neuropathology

The neuropathological features of DRPLA include[@takeda1994]:

• Dentatorubral degeneration: degeneration of the dentate nucleus in the cerebellum and the red nucleus in the midbrain
• Pallidoluysian degeneration: degeneration of the globus pallidus and the subthalamic nucleus
• Atrophy of the cerebral cortex and white matter: observed in cases with longer disease duration
• Loss of Purkinje cells: in the cerebellar cortex
• Neuronal loss and gliosis: throughout the cerebellum, brainstem, and basal ganglia

Molecular Mechanisms

The pathogenesis of DRPLA involves multiple interconnected mechanisms[@suzuki2020]:

1. Protein Aggregation

• Mutant atrophin-1 forms insoluble aggregates that accumulate in the cytoplasm and nucleus of neurons
• These aggregates sequester other cellular proteins, including transcription factors and molecular chaperones
• The aggregates are thought to be toxic to neurons through loss-of-function and gain-of-function mechanisms

• Atrophin-1 normally functions as a transcriptional co-repressor
• The mutant protein disrupts normal transcriptional regulation by sequestering transcription factors such as CREB-binding protein (CBP)
• Dysregulation of genes involved in neuronal survival, mitochondrial function, and synaptic plasticity contributes to neurodegeneration

• Evidence suggests that mutant atrophin-1 impairs mitochondrial function
• Reduced mitochondrial respiratory chain activity leads to energy deficiency and increased oxidative stress
• Calcium homeostasis is disrupted, leading to excitotoxicity

• Activated microglia and astrocytes are observed in post-mortem DRPLA brains
• Pro-inflammatory cytokines contribute to neuronal dysfunction and death

Clinical Features

Core Symptoms

The clinical presentation of DRPLA varies with age of onset[@hirai2001]:

Adult-onset DRPLA (after age 20):

• Progressive cerebellar ataxia (most common presenting symptom)
• Chorea and choreoathetosis (involuntary movements)
• Myoclonus (muscle jerks)
• Cognitive decline and dementia
• Psychiatric symptoms (depression, anxiety, psychosis)

• Myoclonus and seizures (more prominent than in adult form)
• Progressive cerebellar ataxia
• Behavioral problems and intellectual disability
• More rapid disease progression

Disease Progression

The disease is progressive, with median survival of approximately 14-20 years after symptom onset[@kanemoto1999]. Death typically results from complications such as aspiration pneumonia, infections, or injuries related to falls.

Disease stages[@yamada2002]:

Diagnosis

Clinical Diagnosis

The diagnosis of DRPLA is based on[@shioiri2014]:

Genetic Testing

Molecular genetic testing involves[@saito2005]:

• Polymerase chain reaction (PCR) to determine the number of CAG repeats
• Normal: < 36 repeats
• Intermediate (reduced penetrance): 36-39 repeats
• Full penetrance: ≥ 40 repeats (typically 48-88 repeats in affected individuals)

Differential Diagnosis

DRPLA must be differentiated from other causes of cerebellar ataxia[@klockgether2014]:

• Other spinocerebellar ataxias (SCAs)
• Huntington's disease
• Multiple system atrophy (MSA)
• Friedreich's ataxia
• Secondary causes (vascular, toxic, metabolic)

Neuroimaging

MRI findings in DRPLA include[@hoshino1995]:

• Cerebellar atrophy (especially of the cerebellar hemispheres)
• Atrophy of the brainstem (particularly the pons)
• Dilatation of the fourth ventricle
• In advanced cases, cerebral cortical and white matter atrophy
• The "hot cross bun sign" may be observed in the brainstem

Management

Symptomatic Treatment

There is currently no disease-modifying therapy for DRPLA. Treatment is supportive and symptomatic[@saiki2013]:

1. Movement Disorders

• Myoclonus: Clonazepam, valproic acid, levetiracetam
• Chorea: Tetrabenazine, olanzapine, antipsychotics
• Ataxia: Physical therapy, assistive devices

• Antiepileptic drugs: Valproic acid, clonazepam, levetiracetam
• Avoid carbamazepine if possible

• Cognitive impairment: Acetylcholinesterase inhibitors may provide modest benefit
• Depression: SSRIs, other antidepressants
• Psychosis: Atypical antipsychotics

• Physical therapy for gait training and balance
• Occupational therapy for independence in daily activities
• Speech therapy for dysarthria and swallowing difficulties
• Nutritional support to maintain weight

Experimental Therapies

Several therapeutic approaches are under investigation[@yamada2015]:

1. Gene Silencing

• Antisense oligonucleotides (ASOs) targeting mutant ATN1 mRNA
• RNA interference (RNAi) approaches
• Goal: Reduce production of mutant atrophin-1 protein

• Molecular chaperones to prevent protein misfolding and aggregation
• Aggregation inhibitors
• Autophagy enhancers to clear protein aggregates

• Novel pharmacological agents for myoclonus and chorea
• Neuroprotective agents

• Transplantation of neural stem cells or progenitor cells
• Goal: Replace lost neurons and provide neurotrophic support

Animal Models

Several animal models of DRPLA have been developed to study disease mechanisms and test therapeutic interventions[@tanaka2013]:

1. Mouse Models

• Transgenic mice expressing mutant human ATN1 with expanded polyglutamine repeats
• Knock-in mice with expanded CAG repeats in the endogenous mouse ATN1 gene
• Phenotype: Ataxia, myoclonus, cognitive deficits, premature death

• Fruit fly models expressing mutant ATN1
• Used for genetic screening and drug discovery

• Induced pluripotent stem cells (iPSCs) derived from DRPLA patients
• Neuronal cultures for mechanistic studies and drug screening

Research Directions

Current research priorities for DRPLA include[@shimohata2013a]:

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Comparison with Other Polyglutamine Diseases

DRPLA shares many pathogenic mechanisms with other polyglutamine diseases, particularly Huntington's disease and several spinocerebellar ataxias[@shimohata2007]. Understanding these shared pathways is crucial for developing therapies that may benefit multiple diseases.

Shared Pathogenic Mechanisms

1. Protein Aggregation
All polyglutamine diseases are characterized by the formation of intracellular protein aggregates containing the mutant protein[@suzuki2009a]. These aggregates:

• Are composed of insoluble, fibrillar aggregates of the mutant protein
• Sequester other proteins including transcription factors, molecular chaperones, and components of the ubiquitin-proteasome system
• May propagate between cells in a prion-like manner
• Form in both the cytoplasm and nucleus of neurons

• Interact with and sequester transcriptional co-activators such as CBP (CREB-binding protein)
• Alter the function of histone acetyltransferases
• Lead to widespread changes in gene expression
• Affect genes involved in neuronal survival, mitochondrial function, and synaptic plasticity

• The mutant atrophin-1 protein directly or indirectly affects mitochondrial function
• Reduced ATP production leads to energy failure
• Increased reactive oxygen species (ROS) production causes oxidative stress
• Calcium buffering capacity is impaired

• Mutant atrophin-1 impairs autophagic flux
• Lysosomal function is compromised
• Protein aggregates accumulate due to impaired clearance

Disease-Specific Features

While sharing common mechanisms, each polyglutamine disease has unique features[^37]:

| Feature | DRPLA | HD | SCA1 | SCA3/MJD |
|---------|-------|-----|------|----------|
| Gene | ATN1 | HTT | ATXN1 | ATXN3 |
| Protein | Atrophin-1 | Huntingtin | Ataxin-1 | Ataxin-3 |
| Primary degeneration | Dentate nucleus, globus pallidus | Striatum, cortex | Cerebellum, Purkinje cells | Brainstem, cerebellum |
| Key symptoms | Ataxia, myoclonus, chorea | Chorea, dementia | Ataxia, dysarthria | Ataxia, dystonia |

Cross-Disease Therapeutic Approaches

Given the shared mechanisms, therapies targeting common pathways may benefit multiple polyglutamine diseases[^38]:

Patient Resources and Support

Organizations

Patients and families affected by DRPLA can access support through various organizations[^39]:

• National Ataxia Foundation (NAF): Provides education, support, and research advocacy for ataxia patients
• American Academy of Neurology (AAN): Offers resources for patients with neurological disorders
• Rare Disease Organizations: Connect patients with rare neurodegenerative diseases

Genetic Counseling

Genetic counseling is essential for families with DRPLA[^40]:

• Testing for at-risk individuals
• Discussion of inheritance patterns and recurrence risks
• Preconception and prenatal testing options
• Psychological support for patients and families

Clinical Trials

Several clinical trials are investigating potential treatments for DRPLA and related polyglutamine diseases[^41]:

• ASO-based gene silencing trials for other polyglutamine diseases may inform DRPLA trials
• Neuroprotective agents are being tested in related conditions
• Symptomatic treatments continue to be optimized

Future Directions

Biomarker Development

Reliable biomarkers are needed for clinical trials[^42]:

• Neuroimaging biomarkers: MRI measures of disease progression
• Biochemical biomarkers: Levels of mutant protein or downstream markers in cerebrospinal fluid
• Clinical biomarkers: Sensitive measures of myoclonus and ataxia progression

Gene Therapy Advances

Recent advances in gene therapy offer new therapeutic possibilities[^43]:

• Improved viral vectors for gene delivery
• CRISPR-based approaches for gene correction
• Non-viral delivery methods

Personalized Medicine

Future approaches may include personalized therapies based on individual patient characteristics[^44]:

• Genotype-phenotype correlations to predict disease course
• Tailored treatment approaches based on specific mutations
• Combination therapies targeting multiple pathways

International Collaboration

Given the rarity of DRPLA, international collaboration is essential[^45]:

• Patient registries to facilitate natural history studies
• Shared data and sample repositories
• Coordinated clinical trial efforts

Conclusion

Dentatorubral-Pallidoluysian Atrophy (DRPLA) is a rare but devastating neurodegenerative disorder that shares many pathogenic mechanisms with other polyglutamine diseases. While currently there is no cure, advances in understanding the molecular basis of the disease have identified multiple therapeutic targets. Gene-silencing approaches, aggregation inhibitors, and neuroprotective agents offer hope for disease-modifying treatments in the future. Continued research and international collaboration will be essential to translate these scientific advances into effective therapies for patients with DRPLA.

[@shimohata2007]: Shimohata T, et al. Dentatorubral-pallidoluysian atrophy (DRPLA): the polyglutamine disease with the most widespread brain degeneration. J Neurol. 2007;254(10):1389-1396. PMID: [#17962949](https://pubmed.ncbi.nlm.nih.gov/17962949/).

[@suzuki2009a]: Suzuki K, et al. Molecular pathogenesis of polyglutamine diseases. Neuropathology. 2009;29(4):516-522. PMID: [#19222854](https://pubmed.ncbi.nlm.nih.gov/19222854/).

[@cha2000]: Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000;23(9):387-392. PMID: [#10963486](https://pubmed.ncbi.nlm.nih.gov/10963486/).

[@saute2021]: Saute JA, et al. Mitochondrial dysfunction in neurodegenerative diseases. J Neurol Sci. 2021;427:117531. PMID: [#34022778](https://pubmed.ncbi.nlm.nih.gov/34022778/).

[@rubinsztein2006]: Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006;443(7113):780-786. PMID: [#17051204](https://pubmed.ncbi.nlm.nih.gov/17051204/).

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Dentatorubral-Pallidoluysian Atrophy (DRPLA) discovered through SciDEX knowledge graph analysis: